News
PLUR
4.620
+3.13%
0.140
Pluri Proposes Extension of Convertible Bond Maturity to Key Investor
TipRanks · 4d ago
Pluri Inc. Faces Financial Challenges Amid Continued Innovation
TipRanks · 4d ago
Pluri: Fiscal Q2 Earnings Snapshot
Barchart · 5d ago
Pluri Ltd. Strengthens Financial Position Through Capital Raising
TipRanks · 5d ago
Weekly Report: what happened at PLUR last week (0203-0207)?
Weekly Report · 6d ago
Pluri secures additional $3.5 million investment
Seeking Alpha · 02/04 12:50
Pluri secures additional $3.5M investment from Merchant Adventure Fund
TipRanks · 02/04 12:16
Weekly Report: what happened at PLUR last week (0127-0131)?
Weekly Report · 02/03 10:56
Pluri Strengthens Leadership Amid Strategic Board Appointment
TipRanks · 01/29 14:15
Weekly Report: what happened at PLUR last week (0120-0124)?
Weekly Report · 01/27 10:59
Pluri gets $6.5M investment from Alejandro Weinstein, enters cacao market
TipRanks · 01/23 14:25
Pluri Secures $6.5 Mln Investment To Buy 71% Of Kokomodo To Enter Cocao Market
NASDAQ · 01/23 13:42
Pluri secures $6.5M investment, acquires 71% stake in Kokomodo for $4.5M
TipRanks · 01/23 12:25
Pluri Secures $6.5 Million Strategic Investment at Premium to Market, Enters Cacao Market Through Acquisition
Barchart · 01/23 06:15
Weekly Report: what happened at PLUR last week (0113-0117)?
Weekly Report · 01/20 10:51
Weekly Report: what happened at PLUR last week (0106-0110)?
Weekly Report · 01/13 10:52
Weekly Report: what happened at PLUR last week (1230-0103)?
Weekly Report · 01/06 10:59
Weekly Report: what happened at PLUR last week (1223-1227)?
Weekly Report · 12/30/2024 10:54
Weekly Report: what happened at PLUR last week (1216-1220)?
Weekly Report · 12/23/2024 10:59
Pluri congratulates Mesoblast, CEO on FDA approval of MSC-based therapy
TipRanks · 12/19/2024 13:20
More
Webull provides a variety of real-time PLUR stock news. You can receive the latest news about Pluri Inc through multiple platforms. This information may help you make smarter investment decisions.
About PLUR
Pluri Inc., formerly known as Pluristem Therapeutics Inc., is an Israel-headquartered company engaged in the research and provision of cell-based products directed for a range of industries. The Company is focused on researching and developing cell transformation and 3D cell expansion technologies that allow mass production of cells. The products of the Company are used for the pharmaceutical industry as well as for food technology, agriculture technology, and cell-based materials. In the pharmaceutical sector, the Company's preclinical and clinical programs explore multiple therapeutic areas such as vascular disease, inflammation-related conditions, muscle injuries, and hematological disorders. In the food sector, the Firm produces cultivated meat, cultivated fish, and seafood, as well as plant-based products. In agriculture, the Company develops alternative farming methods. The Company has a portfolio of over 140 granted patents in approximately 52 countries.